TELIX PHARMACEUTICALS LIMITED news, videos and press releases - Page 2
For more news please use our advanced search feature.
TELIX PHARMACEUTICALS LIMITED - More news...
TELIX PHARMACEUTICALS LIMITED - More news...
- Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
- First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
- Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
- Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
- ‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
- IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
- Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
- Telix Announces Reorganisation to Deliver on Strategic Priorities
- Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
- Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
- Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
- Telix Successfully Prices A$650 Million Convertible Bonds
- Telix Successfully Prices A$650 Million Convertible Bonds
- FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
- Telix Announces A$600 Million Convertible Bonds Offering
- Telix Announces A$600 Million Convertible Bonds Offering
- Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade
- Q2 2024 Revenue and Business Highlights, Guidance Upgrade
- Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
- Telix Announces Launch of Proposed Initial Public Offering in the United States
- Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
- Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
- Telix Submits NDA for New Prostate Cancer Imaging Agent
- Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
- Telix Files Registration Statement for Proposed Initial Public Offering in the United States
- Q1 2024 Revenue and Business Update
- Q1 2024 Revenue and Business Update
- TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
- World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
- QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
